Evidence map›Paper›PMID 37745450›Full record

ArticlebioRxiv : the preprint server for biology2023

Acod1 Expression in Cancer Cells Promotes Immune Evasion through the Generation of Inhibitory Peptides.

James H Schofield, Joseph Longo, Ryan D Sheldon, Emma Albano, Mark A Hawk, Sean Murphy, Loan Duong, Sharif Rahmy, Xin Lu, Russell G Jones and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

James H SchofieldDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
Joseph LongoDepartment of Metabolism and Nutritional Programming, Van Andel Institute, Grand Rapids, Michigan 49503, USA.
Ryan D SheldonMass Spectrometry Core, Van Andel Institute, Grand Rapids, Michigan 49503, USA.
Emma AlbanoDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
Mark A HawkDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
Sean MurphyDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
Loan DuongDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
Sharif RahmyDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
Xin LuDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
Russell G JonesDepartment of Metabolism and Nutritional Programming, Van Andel Institute, Grand Rapids, Michigan 49503, USA.
Zachary T SchaferDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556 USA.
University of Notre Dame · USVan Andel Institute · US

Funding

Ketone Body Metabolism in CD8+ T Cell ResponsesR01AI165722 · NIAID · VAN ANDEL RESEARCH INSTITUTE · PI JONES, RUSSELL GRAHAM · 2022 to 2025
$3.3M
Mitophagy-Mediated Cell Death in Mammary TumorigenesisR01CA262439 · NCI · UNIVERSITY OF NOTRE DAME · PI SCHAFER, ZACHARY T. · 2021 to 2025
$2.1M
Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin EffectorR01CA248033 · NCI · UNIVERSITY OF NOTRE DAME · PI LU, XIN · 2020 to 2024
$1.8M
Immunosuppression and Metabolic Rewiring in Tumor-infiltrating NeutrophilsR01CA280097 · NCI · UNIVERSITY OF NOTRE DAME · PI Xin Lu · 2023 to 2026
$1.4M
Utilization of Fasting Mimicking Diets to Treat and Prevent Clear Cell Renal Cell CarcinomaF99CA274694 · NCI · UNIVERSITY OF NOTRE DAME · PI MURPHY, SEAN · 2022 to 2023
$96k
NCI NIH HHS F99 CA274694NCI NIH HHS R01 CA248033NCI NIH HHS R01 CA262439NCI NIH HHS R01 CA280097NIAID NIH HHS R01 AI165722
6 · The paper itself

Abstract

Targeting PD-1 is an important component of many immune checkpoint blockade (ICB) therapeutic approaches. However, ICB is not an efficacious strategy in a variety of cancer types, in part due to immunosuppressive metabolites in the tumor microenvironment (TME). Here, we find that αPD-1-resistant cancer cells produce abundant itaconate (ITA) due to enhanced levels of aconitate decarboxylase (Acod1). Acod1 has an important role in the resistance to αPD-1, as decreasing Acod1 levels in αPD-1 resistant cancer cells can sensitize tumors to αPD-1 therapy. Mechanistically, cancer cells with high Acod1 inhibit the proliferation of naïve CD8

Identifiers

PMID37745450
PMCPMC10515953
OpenAlexW4386811225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.